DECADRON-LA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DECADRON-LA (DECADRON-LA).
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory and immunosuppressive effects; suppresses migration of polymorphonuclear leukocytes, reverses increased capillary permeability, and reduces cytokine production.
| Metabolism | Primarily hepatic, via CYP3A4. |
| Excretion | Renal (<5% unchanged), hepatic metabolism with inactive metabolites excreted renally and fecally; urine and bile are minor routes. Exact % not specified for Decadron-LA (dexamethasone acetate), but dexamethasone is predominantly metabolized and metabolites are excreted renally (~80% of dose) and fecally (~20%). |
| Half-life | Terminal elimination half-life is approximately 3-4 hours for dexamethasone, but due to the acetate ester in Decadron-LA, absorption is prolonged, leading to an extended duration of action. The apparent half-life after intramuscular administration is about 3-4 days (72-96 hours) due to slow release from the injection site. |
| Protein binding | Dexamethasone is approximately 77% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Vd for dexamethasone is approximately 0.8-1.0 L/kg (mean ~0.9 L/kg), indicating distribution into total body water. |
| Bioavailability | Oral: 80-90% (dexamethasone base). Intramuscular: 100% (assuming absorption from depot). Intravenous: 100%. |
| Onset of Action | Intramuscular: 1-2 hours for systemic effects (anti-inflammatory). Intra-articular/intralesional: 24-72 hours for local effects. Intravenous: immediate. Oral: within 1-2 hours. |
| Duration of Action | Intramuscular: 1-3 weeks depending on dose, due to slow release from the acetate salt. Intra-articular: 3 days to 3 weeks. Intravenous/oral: duration of action 12-36 hours (anti-inflammatory). |
Dexamethasone acetate (DECADRON-LA) 8-16 mg intramuscularly every 1-3 weeks; adjust based on response and tolerance.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for GFR >10 mL/min; for GFR <10 mL/min, consider reducing dose by 25-50% due to prolonged half-life. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Reduce dose by 75% or use alternative with shorter half-life. |
| Pediatric use | 0.02-0.3 mg/kg/dose intramuscularly every 1-3 weeks; not to exceed 8 mg as initial dose; titrate based on response. |
| Geriatric use | Initiate at lower end of dosing range (8 mg intramuscularly) and titrate slowly due to increased risk of osteoporosis, hyperglycemia, and immunosuppression; monitor bone density and blood glucose. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DECADRON-LA (DECADRON-LA).
| Breastfeeding | Enters breast milk; M/P ratio 0.25–0.5. Low doses (prednisone ≤20 mg/day) generally compatible. High doses may cause neonatal adrenal suppression. Monitor infant for growth and adrenal function. |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (odds ratio 3.35) and cardiovascular defects. Second/third trimester: Fetal adrenal suppression, IUGR, oligohydramnios. Chronic use increases risk of preterm birth. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Systemic fungal infections","Hypersensitivity to dexamethasone or any component of the formulation"]
| Precautions | ["May cause immunosuppression and increase susceptibility to infections.","Adrenal suppression with prolonged therapy; taper gradually.","Exacerbation of systemic fungal infections; do not use in active fungal infections unless specific antifungal therapy is administered.","Withdrawal symptoms including adrenal insufficiency, fever, myalgia, arthralgia, and malaise.","Kaposi sarcoma has been reported; discontinuation may result in clinical remission.","Avoid live vaccines in patients receiving immunosuppressive doses.","Monitor blood pressure, blood glucose, and electrolytes during prolonged therapy."] |
Loading safety data…
| Blood pressure, blood glucose (maternal). Fetal ultrasound for growth and amniotic fluid index (every 4 weeks if chronic therapy). Fetal heart rate monitoring if preterm labor risk. |
| Fertility Effects | May inhibit ovulation (dose-dependent) via suppression of LH/FSH. Reversible upon discontinuation. No evidence of permanent infertility. |